Lausanne University Hospital

Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck

Retrieved on: 
Thursday, January 18, 2024
Hope, OBT, Neoplasm, Patient, Radiation therapy, MD, ADC, Neck, PD-1, Radiation, Head, NSCLC, ACC, Doctor of Philosophy, Antigen, Ovarian cancer, Lausanne University Hospital, Lung, CPI, CD205, Pharmaceutical industry

OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients.

Key Points: 
  • OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients.
  • The CD205 receptor is highly overexpressed in solid and liquid tumors with high unmet need, including gastric, lung and ovarian cancer.
  • We look forward to demonstrating the potential value of OBT076, with the hope to provide meaningful benefit for ACC patients.
  • Trial arms are investigating OBT076 both as a monotherapy and in combination with a CPI in these tumors.

Biospectal OptiBP Receives First-Ever CE Mark for a Smartphone Blood Pressure Monitoring App

Retrieved on: 
Wednesday, December 6, 2023
Apps, Applications, Mobile, Wireless, Technology, Medical Devices, Software, Audio, Video, Other Health, General Health, Health, Data Management, World Health Organization, Hypertension, Research, Android, Electronics, MDR, Smartphone, Patient, European, Algorithm, CE, Google Play, Anesthesiology, System, Lausanne University Hospital, Partnership, CHUV, Certification, Telehealth, Professor, Blood pressure, Medical device, Pharmaceutical industry, Microtechnology

Biospectal , the remote monitoring and biosensing software company, today announced it has received European CE MDR Class IIa medical device certification for its optical fingertip blood pressure monitoring app, OptiBP™ — the first and only software app worldwide to receive the CE mark for measuring blood pressure on a smartphone.

Key Points: 
  • Biospectal , the remote monitoring and biosensing software company, today announced it has received European CE MDR Class IIa medical device certification for its optical fingertip blood pressure monitoring app, OptiBP™ — the first and only software app worldwide to receive the CE mark for measuring blood pressure on a smartphone.
  • The Biospectal OptiBP app uses the built-in camera lens on a smartphone to record an individual’s blood flow easily via their fingertip.
  • OptiBP records fingertip blood flow optically and transforms that information into a pulse wave that it analyzes to estimate blood pressure.
  • By allowing blood pressure to be measured at the ‘point of patient,’ OptiBP enables more frequent, trackable and shareable information to support better blood pressure management and better life outcomes.

RaySearch Laboratories: Interim report January 1 - September 30, 2023

Retrieved on: 
Friday, November 17, 2023
Paul Scherrer Institute, CFO, Mass, Cyberknife, CET, University Medical Center Groningen, RaySearch Laboratories, Lausanne University Hospital, University, Partnership, CHUV, Pharmaceutical industry, Nursing, Flour

RaySearch and MedAustron expand their partnership through a new strategic research agreement.

Key Points: 
  • RaySearch and MedAustron expand their partnership through a new strategic research agreement.
  • RaySearch's business partner IBA has placed an order for RayStation and RayCare for installation at CRO National Cancer Institute (C.R.O.)
  • RaySearch has received an order from Israel-based P-Cure and is deepening its collaboration focusing on advanced proton therapy solutions.
  • CEO Johan Löf and interim CFO Annika Blondeau Henriksson will present RaySearch's interim report for January - September 2023 at a webcast to be held in English on Friday, November 17, 2023 at 10:00-10:30 a.m. CET.

Aerium Therapeutics Advances Next Generation Antibodies to Protect Immunocompromised Persons Against COVID-19

Retrieved on: 
Wednesday, October 4, 2023
COVID-19, Research, Infectious Diseases, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Aerium, Infection, UNC School of Medicine, RBD, Vaccination, Rockefeller University, SARS-CoV-2, Hook effect, Hope, Person, CHUV, Global Health, Death, EPFL, Immunodeficiency, Fred Hutchinson Cancer Research Center, Therapy, Vaccine, ACE2, Lausanne University Hospital, Tropical Islands Resort, Medicine

AER004 was discovered by Michel Nussenzweig at Rockefeller University and also blocks the RBD in a complementary manner to AER003.

Key Points: 
  • AER004 was discovered by Michel Nussenzweig at Rockefeller University and also blocks the RBD in a complementary manner to AER003.
  • Aerium is pursuing a mAb combination strategy to defend against future viral evolution.
  • Aerium is also initiating development of AER005 for potential inclusion in a future product.
  • The mAbs have been modified to provide long-acting protection and exhibit potent and consistent activity against all previous and predominantly circulating variants.

Advancing Cancer Treatment: Leo Cancer Care and THERYQ Collaborate on Innovative FLASHDEEP Patient Positioning

Retrieved on: 
Sunday, October 1, 2023
CERN, Radiation, Hope, Lausanne University Hospital, European Laboratory for Non-Linear Spectroscopy, CHUV, Organization, FLASH, Patient, Particle physics, Medical imaging, Pharmaceutical industry

This technique has shown promise in targeting cancer cells more effectively while minimizing side effects, making it a potential breakthrough in cancer treatment.

Key Points: 
  • This technique has shown promise in targeting cancer cells more effectively while minimizing side effects, making it a potential breakthrough in cancer treatment.
  • Leo Cancer Care's novel upright patient positioning solution will be integrated into the first unit installed at CHUV.
  • -  Improved Patient Comfort: Innovative upright patient positioning minimizes discomfort during cancer therapy, enhancing patient experience.
  • Both Leo Cancer Care and THERYQ are committed to pushing the boundaries of cancer care, and this collaboration marks a significant milestone in their joint mission to transform the landscape of radiation therapy.

Advancing Cancer Treatment: Leo Cancer Care and THERYQ Collaborate on Innovative FLASHDEEP Patient Positioning

Retrieved on: 
Sunday, October 1, 2023
CERN, Radiation, Hope, Lausanne University Hospital, European Laboratory for Non-Linear Spectroscopy, CHUV, Organization, FLASH, Patient, Particle physics, Medical imaging, Pharmaceutical industry

This technique has shown promise in targeting cancer cells more effectively while minimizing side effects, making it a potential breakthrough in cancer treatment.

Key Points: 
  • This technique has shown promise in targeting cancer cells more effectively while minimizing side effects, making it a potential breakthrough in cancer treatment.
  • Leo Cancer Care's novel upright patient positioning solution will be integrated into the first unit installed at CHUV.
  • -  Improved Patient Comfort: Innovative upright patient positioning minimizes discomfort during cancer therapy, enhancing patient experience.
  • Both Leo Cancer Care and THERYQ are committed to pushing the boundaries of cancer care, and this collaboration marks a significant milestone in their joint mission to transform the landscape of radiation therapy.

Healiva® Announces Strategic Collaboration With Lausanne University Hospital to Manufacture EpiDex® for Severe Chronic Wound Treatment

Retrieved on: 
Tuesday, September 26, 2023
Research, Technology, Medical Devices, Hospitals, University, Other Manufacturing, Health Technology, Education, Science, Biotechnology, Other Technology, Health, Manufacturing, GMP, Advanced Therapy Medicinal Product, Partnership, VLU, Epidermis, European Directive on Traditional Herbal Medicinal Products, Cell, Doctor of Philosophy, CHUV, Patient, Education minister, Mouth ulcer, Growth, Skin, Lausanne University Hospital, Pharmaceutical industry

Healiva ®, a patient-centric company delivering life-enhancing precision medicine for chronic wounds, announced today a strategic collaboration with Lausanne University Hospital (CHUV, ‘Centre Hospitalier Universitaire Vaudois’) for the manufacturing and approval of its autologous epidermal equivalent, Epidex ®.

Key Points: 
  • Healiva ®, a patient-centric company delivering life-enhancing precision medicine for chronic wounds, announced today a strategic collaboration with Lausanne University Hospital (CHUV, ‘Centre Hospitalier Universitaire Vaudois’) for the manufacturing and approval of its autologous epidermal equivalent, Epidex ®.
  • Originating from the patient’s own hair follicles, EpiDex® enables non-invasive treatment of severe chronic venous leg ulcers (VLUs).
  • “We are very pleased to partner with CHUV on EpiDex® production”, said Dr. Priyanka Dutta-Passecker, Co-founder and CEO of Healiva.
  • “We are fully committed to leveraging our experience in manufacturing technologies to support Healiva 's manufacture of EpiDex®.”

Six-Year Follow-Up Data on CheckMate 227 Survival and Quality of Life Benefits Unveiled for Patients with Metastatic NSCLC and Nivolumab + Ipilimumab Treatment

Retrieved on: 
Sunday, September 10, 2023
Survival, International Association, Lung cancer, Quality of life, NSCLC, Lung, Patient, Checkmate, ECOG, Ipilimumab, Quality of life (healthcare), Nivolumab, Conference, Lausanne University Hospital, Medical imaging, Nursing

Research findings from the CheckMate 227 trial will be presented, shedding light on the extraordinary six-year survival and quality of life benefits associated with first-line nivolumab plus ipilimumab therapy.

Key Points: 
  • Research findings from the CheckMate 227 trial will be presented, shedding light on the extraordinary six-year survival and quality of life benefits associated with first-line nivolumab plus ipilimumab therapy.
  • "The evidence we present offers a compelling case for the transformative potential of nivolumab + ipilimumab in metastatic NSCLC treatment.
  • Patients were divided into different cohorts based on tumor PD-L1 expression levels and randomized to receive nivolumab plus ipilimumab, nivolumab, nivolumab plus chemotherapy or chemotherapy alone.
  • "The evidence we present offers a compelling case for the transformative potential of nivolumab plus ipilimumab in metastatic NSCLC treatment.

RaySearch Laboratories : Interim report January 1 - June 30, 2023

Retrieved on: 
Friday, August 25, 2023
Proton, Cyberknife, Partnership, EU, RaySearch Laboratories, Medical examiner, CEST, Proton therapy, CFO, Research, University Medical Center Groningen, Lausanne University Hospital, Pharmaceutical industry, Flour

New York University Langone Hospital, USA, placed an order for RayStation, which will replace its current treatment planning system.

Key Points: 
  • New York University Langone Hospital, USA, placed an order for RayStation, which will replace its current treatment planning system.
  • Shinva, a Chinese radiation therapy machine manufacturer, placed an order for 15 RayPlan systems for onwards sales to customers in China.
  • The total number of registered shares in RaySearch amounts to 34,282,773 of which 7,654,975 are Class A shares and 26,627,798 are Class B shares.
  • CEO Johan Löf and interim CFO Annika Blondeau Henriksson will present RaySearch's interim report for January -June 2023 at a webcast to be held in English on Friday, August 25, 2023 at 10:00-10:30 a.m. CEST.

RaySearch to present the latest advances in RayStation, RayCare and RayIntelligence at AAPM 2023

Retrieved on: 
Monday, July 24, 2023
Photon, LET, Health, AAPM, RaySearch Laboratories, DICOM, Research, Lausanne University Hospital, Doctor of Philosophy, Véronique, University of Lausanne, Congress, Linear energy transfer, Medical imaging

STOCKHOLM, July 23, 2023 /PRNewswire/ -- The latest version of RayStation includes among others support for automatic field-in-field planning for photons, a method that generates homogeneous and conformal dose distributions by combining a few subfields, as well as point-based optimization of brachy plans, and faster loading of data. Attendees will also be able to experience the next steps in workflow improvements for dosetracking and adaptive replanning. Within particle therapy planning, support for proton arcs and robust optimization based on linear energy transfer (LET) will be showed.

Key Points: 
  • RaySearch will be showcasing the latest software innovations at AAPM in Houston, Texas, July 23-27.
  • Attendees will be able to book demonstrations of RayStation®* treatment planning system, RayCare®* oncology information system, and the cloud-based oncology analytics system RayIntelligence® during the congress.
  • Attendees will also be able to experience the next steps in workflow improvements for dosetracking and adaptive replanning.
  • Within particle therapy planning, support for proton arcs and robust optimization based on linear energy transfer (LET) will be showed.